Azalanstat
Anti-obesity drug
- None
- 4-({[(2S,4S)-2-[2-(4-Chlorophenyl)ethyl]-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}sulfanyl)aniline
- 143393-27-5
N
- 60876
- 54858
Y
- 2NL79NI1WS
- D03025 Y
- ChEMBL70611 Y
- Interactive image
- Clc1ccc(cc1)CC[C@@]2(OC[C@H](O2)CSc3ccc(N)cc3)Cn4ccnc4
InChI
- InChI=1S/C22H24ClN3O2S/c23-18-3-1-17(2-4-18)9-10-22(15-26-12-11-25-16-26)27-13-20(28-22)14-29-21-7-5-19(24)6-8-21/h1-8,11-12,16,20H,9-10,13-15,24H2/t20-,22-/m0/s1Y
- Key:VYNIUBZKEWJOJP-UNMCSNQZSA-NY
N
Y (what is this?)Azalanstat (INN,[1] codenamed RS-21607) is an anti-obesity drug acting as a lanosterol 14α-demethylase inhibitor.[2][3]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names (Rec. INN): List 36" (PDF). World Health Organization. p. 141. Retrieved 3 January 2017.
- ^ Walker KA, Kertesz DJ, Rotstein DM, Swinney DC, Berry PW, So OY, et al. (July 1993). "Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering". Journal of Medicinal Chemistry. 36 (15): 2235–7. doi:10.1021/jm00067a022. PMID 8340925.
- ^ Burton PM, Swinney DC, Heller R, Dunlap B, Chiou M, Malonzo E, et al. (August 1995). "Azalanstat (RS-21607), a lanosterol 14 alpha-demethylase inhibitor with cholesterol-lowering activity". Biochemical Pharmacology. 50 (4): 529–44. doi:10.1016/0006-2952(95)00152-p. PMID 7646560.
- v
- t
- e
Antiobesity agents/Anorectics (A08)
antagonists
glucagon agonists
receptor agonists
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
